Pharmacel® 200 - Advanced MCC Grade for Robust Formulation and Process Reliability
Azelis, as the official distributor of DFE Pharma, is pleased to introduce Pharmacel® 200 a new grade of microcrystalline cellulose (MCC) designed to address key challenges in modern pharmaceutical formulation and manufacturing.
Microcrystalline cellulose grades differ primarily in particle size, which directly impacts flowability, compressibility and overall process performance. As pharmaceutical manufacturers increasingly focus on process reliability, batch-to-batch consistency and formulation robustness, the selection of the right MCC grade becomes an important factor in successful product development and scale-up.
Grade | Mean particle size | Key functionality |
|---|---|---|
~50 µm | High binding capacity. | |
~100 µm | Balanced flow and compressibility. | |
~100µm | Low moisture content (LOD <1.5%) suitable for moisture-sensitive APIs. | |
~200 µm | Superior flowability and process stability. |
What makes Pharmacel® 200 different?
Increasing particle size generally improves powder flowability and reduces cohesiveness. Due to its larger particle size, Pharmacel® 200 supports enhanced die-filling uniformity and can help reduce segregation in systems with similar particle size distributions.
Although larger particles provide a slightly lower surface area compared with finer MCC grades, Pharmacel® 200 offers a balanced compaction behaviour despite larger particle size while still ensuring robust tablet strength. This makes it particularly suitable for formulations where both flow performance and reliable compaction are required.
Benefits for manufacturing performance
Pharmacel® 200 is specifically optimised for direct compression (DC). Compared with MCC 101 and MCC 102 grades, it offers superior flowability and more stable powder flow, supporting consistent die filling during high-speed tableting.
This contributes to reduced variability in tablet weight and content uniformity, particularly in demanding production environments. Pharmacel® 200 also supports improved process robustness during scale-up and high-speed manufacturing, while reducing dependence on flow aids in some formulations.
Compared with finer MCC grades, Pharmacel® 200 offers an improved flow function coefficient, stable die filling at high turret speeds and lower sensitivity to process fluctuations. From an R&D perspective, this can support an easier transition from lab scale to production and reduce the need for re-optimisation during scale-up.
Impact on tablet Quality and Stability
MCC primarily deforms plastically, forming strong interparticle bonds during compression. Pharmacel® 200 enables formulators to achieve reliable tablet tensile strength across a range of compression forces, while providing stable compaction behaviour and supporting improved reproducibility. In well-optimised formulations, it may also help reduce sticking.
Pharmacel® 200 also contributes to consistent hardness and friability across batches. Its controlled porosity helps maintain a stable physical structure over time and reduces the risk of common tableting issues such as capping and lamination.
Critical Quality attributes supporting formulation
Pharmacel® 200 offers ultra-low nitrite levels, typically below 25 ppb, supporting nitrosamine risk mitigation strategies. This makes it suitable for formulations with amine-containing APIs where nitrosamine risk is under particular scrutiny.
The grade also contains minimal dark particles, helping to improve the visual quality and consistency of solid dosage forms.
Batch-to-batch consistency is controlled by design, reducing variability in compressibility, flow and moisture behaviour. This supports technology transfer, process validation and greater predictability during pharmaceutical development and manufacturing.
Controlled moisture content of no more than 5% provides a predictable impact on powder behaviour and tablet compression.
Impact on drug release performance
Immediate Release Formulations
In immediate release (IR) formulations, Pharmacel® 200 contributes to fast and consistent disintegration. Its relatively open tablet structure and controlled porosity support enhanced liquid penetration, helping to achieve reproducible dissolution profiles.
In immediate release (IR) formulations, Pharmacel® 200 contributes to fast and consistent disintegration. Its relatively open tablet structure and controlled porosity support enhanced liquid penetration, helping to achieve reproducible dissolution profiles.
Modified and Extended Release Systems
Although MCC is not a release-controlling polymer, it plays an important structural role in modified and extended release systems. Pharmacel® 200 acts as a matrix-supporting excipient and can modulate porosity and medium penetration.
Although MCC is not a release-controlling polymer, it plays an important structural role in modified and extended release systems. Pharmacel® 200 acts as a matrix-supporting excipient and can modulate porosity and medium penetration.
In combination with polymers such as HPMC, Pharmacel® 200 improves blend uniformity and compressibility, stabilises matrix integrity during hydration and can influence drug diffusion pathways and burst release control.
When to consider Pharmacel® 200
Pharmacel® 200 is particularly suitable for direct compression formulations, blends requiring excellent flow and uniformity, and projects where batch consistency is critical.
It should also be considered for formulations:
- Under nitrosamine scrutiny.
- Products requiring robust scale-up and manufacturing reproducibility.
- Systems where MCC serves as a binder or structural matrix component.
Contact Azelis
Azelis provides technical support for excipient selection, samples for formulation studies, and regulatory and documentation support.
We will be happy to support your evaluation of Pharmacel® 200 in your formulations!
